Will the US be alone in sticking to own quality system regulations
This article was originally published in Clinica
The US FDA has made it clear that it is not going to be sidetracked from its quality system regulation (QSR) despite the recent revision of the global quality management system standard for medical devices, ISO 13485:2003. But does this mean that the US authorities are stubbornly holding onto an outdated system, or are matters better than they seem?
You may also be interested in...
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.